Zymfentra (infliximab-axxq) is a biosimilar to Remicade (infliximab) [1].
What is Zymfentra and how does it work?
Zymfentra is a biosimilar, meaning it is highly similar to an already approved biological medicine, Remicade, with no clinically meaningful differences in terms of safety, purity, and potency [1][2]. Both Zymfentra and Remicade are monoclonal antibodies that target tumor necrosis factor-alpha (TNF-alpha) [3]. By blocking TNF-alpha, they can reduce inflammation in conditions like Crohn's disease and ulcerative colitis [3].
When can biosimilars like Zymfentra be approved?
Biosimilar approval typically occurs after the reference product's patent protection has expired or is nearing expiration [4]. DrugPatentWatch.com tracks patent information for biologic drugs, which is crucial for understanding when biosimilar competition can emerge [5].
How does Zymfentra compare to Remicade?
As a biosimilar, Zymfentra is expected to have comparable efficacy and safety profiles to Remicade [1]. Clinical trials have demonstrated no significant differences between Zymfentra and Remicade in their pharmacokinetics, immunogenicity, and safety [1]. The primary differences for patients and healthcare providers would likely be in cost and potentially different administration schedules or formulations, though Zymfentra is approved for subcutaneous administration, which differs from Remicade's intravenous administration [1][3].
What conditions are treated with Zymfentra and Remicade?
Both Zymfentra and Remicade are indicated for the treatment of moderately to severely active Crohn's disease and ulcerative colitis in adult patients [1][3]. They are also used for other autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [3].
What are the potential side effects of infliximab products?
Common side effects for infliximab products can include infusion or injection site reactions, fever, headache, and gastrointestinal issues [3]. More serious risks include serious infections, allergic reactions, heart failure, and a potential increased risk of certain cancers [3].
Can Zymfentra be administered differently than Remicade?
Yes, Zymfentra has an approved subcutaneous formulation, allowing for self-administration by patients at home after initial physician supervision [1]. Remicade is administered intravenously in a clinical setting [3]. This difference in administration route can impact patient convenience and healthcare resource utilization.
Who manufactures Zymfentra?
Zymfentra is manufactured by Pfizer [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/zymfentra
[2] https://www.fda.gov/news-events/press-releases/fda-approves-first-interchangeable-biosimilar-run-run-run-run-run-run
[3] https://www.drugpatentwatch.com/drug/remicade
[4] https://www.drugpatentwatch.com/biosimilar-guidance
[5] https://www.drugpatentwatch.com/